First-line (1L) ribociclib (RIB) plus endocrine therapy (ET) vs combination chemotherapy (combo CT) in clinically aggressive hormone receptor (HR)+/HER2-advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without liver metastases (mets) from RIGHT Choice.

Sadeleştirilmiş öğe sayfası
dc.contributor.authorEl Saghir, Nagi S.
dc.contributor.authorIm, Seock\\-Ah
dc.contributor.authorAzim, Hamdy A.
dc.contributor.authorEralp, Yesim
dc.contributor.authorYap, Yoon Sim
dc.contributor.authorSandhu, Malwinder S.
dc.contributor.authorAbdel\\-Razeq, Hikmat
dc.contributor.authorGupta, Sudeep
dc.contributor.authorArtamonova, Elena
dc.contributor.authorRihani, Julie
dc.contributor.authorMora Payan, Juan Carlos
dc.contributor.authorChattar, Yogesh
dc.contributor.authorSopher, Gary Mark
dc.contributor.authorGao, Melissa
dc.contributor.authorLu, Yen\\-Shen
dc.date.accessioned2025-10-16T15:11:44Z
dc.date.issued2025
dc.identifier.doi10.1200/JCO.2025.43.16\_suppl.1069
dc.identifier.otherWOS:001509295600001
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/4975
dc.publisherLIPPINCOTT WILLIAMS \& WILKINS
dc.sourceJOURNAL OF CLINICAL ONCOLOGY
dc.titleFirst-line (1L) ribociclib (RIB) plus endocrine therapy (ET) vs combination chemotherapy (combo CT) in clinically aggressive hormone receptor (HR)+/HER2-advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without liver metastases (mets) from RIGHT Choice.
dc.typeMeeting Abstract

Dosyalar

Koleksiyonlar

WOS